Cancer

In the Lab Associated Press

A rare voice box transplant helped a cancer patient speak again, part of a pioneering study

Biotech Jason Mast

STAT Plus: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

Health Rohan Rajeev

STAT Plus: GLP-1s associated with lower risk of 10 obesity-related cancers, study shows

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the third quarter: 19 stock-moving events to watch

Politics Rachel Cohrs Zhang, John Wilkerson, and Lizzy Lawrence

STAT Plus: House panel passes bills to expand Medicare obesity drug coverage, cancer screening

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

In the Lab Angus Chen

STAT Plus: Journal retracts study tied to Micronoma’s effort to create cancer blood test

Health Lev Facher

WHO warns global health toll of alcohol remains ‘unacceptably high’

Biotech Matthew Herper

STAT Plus: Grail, aiming to market a blood test for cancer, faces host of challenges as it debuts on Nasdaq

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

Health Brittany Trang

Hank Green on his ‘Pissing Out Cancer’ comedy special, ulcerative colitis, and the jokes that got cut

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors? 

In the Lab Angus Chen

STAT Plus: New immunotherapy combination could ‘change the landscape’ of cancer treatment

Health Angus Chen

STAT Plus: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Will Geron be acquired? The long-short view

Exclusive John Wilkerson

NIH wanted to make cancer research more diverse. The effort turned out to be a costly failure

The Readout Elaine Chen

Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know

First Opinion Sanket S. Dhruva and Rita F. Redberg

Blood tests for cancer detection aren’t yet ready for prime time

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Psychedelics at the FDA, ASCO recap, & MorphoSys update

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Adam's Take Adam Feuerstein

STAT Plus: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug

Biotech Matthew Herper, Adam Feuerstein, and Angus Chen

STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Biotech Matthew Herper

STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test

Biotech Matthew Herper

STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth